Primrose Therapeutics

About:

Primrose Therapeutics is engaged in the development of treatments for polycystic kidney disease.

Website: http://primrosetherapeutics.com

Description:

Primrose Therapeutics, Inc. is a biotechnology company focused on the development of treatments for Polycystic Kidney Disease (PKD). PKD is one of the most common life-threatening genetic disorders, affecting 600,000 Americans and 12.5 million people worldwide -- more than cystic fibrosis, muscular dystrophy, hemophilia, Down syndrome and sickle cell anemia combined. PKD results in the abnormal growth of cells in the kidney, which eventually lead to the development of bilateral kidney cysts and structural destruction of the kidney. The average lifespan of PKD patients is 64 years -- at least a decade shorter than average. No FDA approved therapies currently exist for this devastating disease.

Total Funding Amount:

$753000

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New York, New York, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)primrosetherapeutics.com

Founders:

Eric Rowinsky

Number of Employees:

1-10

Last Funding Date:

2010-08-17

IPO Status:

Private

Industries:

© 2025 bioDAO.ai